Evangelist Sylvester Karanja, a well-known preacher from Nyeri, has passed away after a long battle with a rare skin condition, fibromatosis His wife, Emily Wairimu, shared their decades-long love ...

J&J subsidiary Janssen-Cilag announced that the European Commission has approved an extension of marketing authorization for a subcutaneous (SC) formulation of Rybrevant (amivantamab), in combination ...

Halozyme Therapeutics (HALO) announced that Janssen-Cilag International NV, a Johnson & Johnson (JNJ) company, has received European Commission marketing authorization of the subcutaneous ...

“The subcutaneous daratumumab-VRd regimen delivers an effective and convenient new standard of care for patients with newly diagnosed multiple myeloma, regardless of transplant eligibility, with ...

In December 2024, the Food and Drug Administration (FDA) approved the PD-1 inhibitor nivolumab (Opvido Qvantig) for use as a subcutaneous injection. Read on to learn more about this new approach ...

Lundbeck has stopped development of a subcutaneous formulation of its migraine drug Lu AG09222 as the Danish drugmaker switches its focus to intravenous delivery after seeing phase 2b data ...

Dublin, April 01, 2025 (GLOBE NEWSWIRE) -- The "Subcutaneous Biologics Market, Industry Trends and Global Forecasts to 2035: Type of Biologic, Type of Therapy, Method of Administration ...

Dublin, April 01, 2025 (GLOBE NEWSWIRE) -- The "Subcutaneous Biologics Market, Industry Trends and Global Forecasts to 2035: Type of Biologic, Type of Therapy, Method of Administration, Fundamental ...

Nivolumab for subcutaneous use co-formulated with recombinant human hyaluronidase (rHuPH20), is indicated across multiple previously approved adult solid tumours as monotherapy, monotherapy ...

For patients with metastatic non–small cell lung cancer (NSCLC), subcutaneous (SC) administration of pembrolizumab works just as well as standard intravenous (IV) administration, phase 3 data ...

Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to ...